<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-68376</identifier>
<setSpec>0212-7199</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">The optic neuromyelitis or syndrome of Devic is an inflammatory and autoimmune illness of the central nervous system. It is characterized by attacks of optic neuritis and myelitis, being able to produce blindness, great neurological disability and even the short term death. Until the moment an effective treatment doesn't exist, the therapy is centred in the treatment of the acute attacks, the medical prevention of the complications and the rehabilitation. This article is a revision of this not very common illness, considering that its prevalence in our country has gone in increase. We compare between the optic neuromyelitis and the multiple sclerosis, being based on the main ones characteristic clinical-epidemic that distinguishes these two pathologies, considered by many clinical variants of oneself illness</dc:description>
<dc:creator>Pentón Rol, G</dc:creator>
<dc:creator>Lopategui Cabezas, I</dc:creator>
<dc:creator>Cervantes Llano, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La neuromielitis optica o síndrome de Devic es una enfermedad inflamatoria, desmielinizante y autoinmune del sistema nervioso central. Se caracteriza por ataques de neuritis óptica y mielitis, pudiendo producir ceguera, gran invalidez neurológica e incluso la muerte a corto plazo. Hasta el momento no existe un tratamiento efectivo, la terapia se centra en el tratamiento de los ataques agudos, la prevención médica de las complicaciones y la rehabilitación. Se realiza una revisión de esta enfermedad poco común, considerando que su prevalencia en nuestro país ha ido en aumento y se establece una comparación entre la neuromiel itisóptica y la esclerosis múltiple, basándose en las principales características clínico-epidemiológicas, que distinguen estas dos patologías, consideradas por muchos variantes clínicas de una misma enfermedad</dc:description>
<dc:source>An Med Interna;25(6): 294-296, jun. 2008.</dc:source>
<dc:identifier>ibc-68376</dc:identifier>
<dc:subject>^d9296^s22012</dc:subject>
<dc:subject>^d9296^s22016</dc:subject>
<dc:subject>^d29486^s22016</dc:subject>
<dc:subject>^d9672^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29486^s22012</dc:subject>
<dc:subject>^d29486^s22032</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29486^s22080</dc:subject>
<dc:subject>^d29510^s22045</dc:subject>
<dc:subject>^d29510^s22066</dc:subject>
<dc:subject>^d24529^s22031</dc:subject>
<dc:type>article</dc:type>
<dc:date>200806</dc:date>
</metadata>
</record>
</ibecs-document>
